VISN 23 offers veterans a range of healthcare services, including acute medical, surgical and psychiatric inpatient services as well as a full range of outpatient services via multiple full-service hospitals, community-based clinics and veterans’ centers.
The XN-Series analyzers perform complete blood counts (CBC); one of the most frequently ordered clinical laboratory tests. In addition, the advanced laser fluorescent flow technology provides additional information used by physicians throughout the continuum of patient care.
The Sysmex® XN Series suite of products includes the Sysmex XN-1000™, the Sysmex XN-2000™, the Sysmex XN-3000™ and the Sysmex XN-9000™ Automated Hematology Analyzers. These configurations are built on the award-winning concept of Silent Design®. This design approach provides a simplified system of operation and user interface that enables an expanded parameter menu for a lab’s evolving clinical needs; configurable modularity for a lab’s workflow needs; and a reagent handling system that saves time and storage space.
The Sysmex XN-Series automated hematology analyzers will help physicians diagnose and treat a wide range of diseases that can impact an aging population, as well as help address network-wide cost and labor pressures. With an estimated volume of more than half a million CBCs per year and an enrolled veteran population of more than 400,000, the XN-Series provides VISN 23 with a powerful, scalable platform that will meet clinical, workflow and informatics needs across the entire enterprise with built-in flexibility to adapt to growth.
“It is an honor to have been entrusted with this important role in serving the healthcare needs of our distinguished veterans,” said John Kershaw, President & CEO, Sysmex America, Inc. “This prestigious and comprehensive partnership is testimony to the transformative aspects of our new XN-Series line, including its high-performance modular design and sophisticated diagnostic capabilities. We look forward to serving VISN 23 and its affiliates as we continue to reshape the future of healthcare at the clinical laboratory level.”